Modern imaging can enhance the entire care pathway of patients with suspected and diagnosed prostate cancer: MRI can help in earlier detection, more precise diagnosis, personalized treatment, convenient follow-up and individual management of advanced disease. We aim to offer a holistic portfolio to support the different stages of this patient journey with high-quality MR imaging.
- Perform a non-invasive prostate MRI exam with surface coils only
- Improve lesion conspicuity in DWI with ZOOMitPRO and RESOLVE
- Improve your reading and reporting with deep-learning based prostate cancer detection and classification with syngo.MR Prostate AI2
- Monitor therapy response earlier with syngo.MR OncoTrend
Improve lesion conspicuity in DWI with ZOOMitPRO and RESOLVE
High-quality diffusion-weighted imaging is of utmost importance in multiparametric MRI of the prostate. With ZOOMitPRO and RESOLVE we provide two independent techniques to tailor the exam to every patient's needs:
RESOLVE reduces blurring and susceptibility to artifacts, i.e. in patients with gas in the rectum or artificial implants. The resulting images are largely free of distortions and provide high spatial resolution. With RESOLVE you are able to improve your clinical capabilities by using a technique that achieves diagnostic images even in patients with metal implants.3
ZOOMitPRO is a method for high-resolution, zoomed FOV imaging, allowing diffusion-weighted images with high contrast and resolution in short acquisition times.
Standardize and ease the communication of your findings with PI-RADS
As part of the basic configuration within the syngo.MR General Engine, syngo.MR Prostate Reading allows for intuitive and comprehensive reading and reporting of multiparametric prostate exams. Using the PI-RADS standard, lesions can be rated on a 5-point Likert scale and findings can be visualized intuitively in a prostate pictogram. This eases communication with referring urologists, ultimately improving your institutional workflows.
Speed up reading and reporting with syngo.MR Prostate AI2
With syngo.MR Prostate AI2 we introduce a key solution to support consistent, high-quality prostate MRI reading and reporting. By deploying artificial intelligence, syngo.MR Prostate AI2 assists in the interpretation of multiparametric Prostate MRI. The deep neural networks of syngo.MR Prostate AI2 are designed to improve the detection and classification of prostate lesions and to reduce the time needed for reporting by generating a pre-populated report.
Link the MR-reading workflow to the US-monitored biopsy
syngo.MR Prostate Biopsy Support provides an automated segmentation of the prostate and estimates the prostate volume, location and contours of biopsy targets can be added. The results need to be approved and finalized by the radiologist and can be exported RTSS format DICOMs to support MR/US-fusion biopsies.
Prostate MRI in the cloud with AI-Rad Companion1
Next to on-premise access through syngo.via, MR prostate biopsy support is also available via the cloud-based AI-Rad Companion. The assistant powered by AI helps you to reduce the burden of basic repetitive tasks and may increase your diagnostic precision when interpreting medical images. Find out more about AI-Rad companion here:
Monitor therapy response early with syngo.MR OncoTrend
syngo.MR OncoTrend as part of the syngo.MR Oncology Workflow enables accurate monitoring of oncological lesions, helping determine whether treatment is effective or needs to potentially be reconsidered. With an intuitive traffic-light color coding, it is possible to visualize functional changes during therapy.
1Pending 510(k) clearance, and not yet commercially available in the United States. Its future availability cannot be guaranteed.
2The product is still under development and not commercially available yet. Its future availability cannot be ensured.
3MR imaging of patients with metallic implants brings specific risks. However, certain implants are approved by the governing regulatory bodies to be MR conditionally safe. For such implants, the previously mentioned warning may not be applicable. Please contact the implant manufacturer for the specific conditional information. The conditions for MR safety are the responsibility of the implant manufacturer, not of Siemens.